Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 7:7:57-62.
doi: 10.2147/DHPS.S78016. eCollection 2015.

Patient-reported outcomes after discontinuation of long-term topical corticosteroid treatment for atopic dermatitis: a targeted cross-sectional survey

Naoko Takahashi-Ando  1 , Mark A Jones  2 , Shigeki Fujisawa  3 , Rokuro Hama  4
Affiliations

Patient-reported outcomes after discontinuation of long-term topical corticosteroid treatment for atopic dermatitis: a targeted cross-sectional survey

Naoko Takahashi-Ando et al. Drug Healthc Patient Saf. .

Abstract

Background: Topical corticosteroid (TCS) treatment is widely prescribed for atopic dermatitis (AD). However, TCS treatment is associated with tachyphylaxis, and discontinuation after long-term use may cause exacerbation of symptoms. Some AD patients are reluctant to use TCS.

Objective: To evaluate patient-reported short- and long-term outcomes after discontinuation of TCS treatment for AD.

Methods: Questionnaires were distributed to adult AD patients (n=1,812) of doctors who did not recommend TCS as first-line therapy for patients who preferred to avoid TCS. Data collected included current TCS use, duration of TCS use, past discontinuation of TCS use, exacerbation of symptoms after discontinuation of TCS use, and limitations to daily activities because of AD.

Results: Of 918 respondents, 97.7% had used TCS, of whom 92.3% had experienced discontinuation of TCS use. After discontinuation, 63.9% experienced their most severe AD symptoms ever. The severity of exacerbation of symptoms was significantly correlated with the length of TCS use (P<0.001). Although most respondents who experienced severe exacerbation after TCS discontinuation were not current TCS users, they generally had fewer current limitations to activities than when AD symptoms were at their worst.

Conclusion: Adult Japanese AD patients who experience severe exacerbation of symptoms immediately after discontinuation of TCS use generally improve over time. We suggest caution regarding long-term TCS treatment in AD patients.

Keywords: adverse effects of corticosteroids; rosacea-like dermatitis; symptom exacerbation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Duration of use of TCS and severity of worsening at withdrawal of TCS. Note: Subjects with unknown duration of TCS use or unknown severity of exacerbation were excluded from this analysis. Abbreviations: TCS, topical corticosteroids; y, years.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 1999;103(1 Pt 1):125–138. - PubMed
    1. Nishioka K. Atopic eczema of adult type in Japan. Australas J Dermatol. 1996;37(Suppl 1):S7–S9. - PubMed
    1. Kligman AM, Frosch PJ. Steroid addiction. Int J Dermatol. 1979;18(1):23–31. - PubMed
    1. Zheng PS, Lavker RM, Lehmann P, Kligman AM. Morphologic investigations on the rebound phenomenon after corticosteroid-induced atrophy in human skin. J Invest Dermatol. 1984;82(4):345–352. - PubMed
    1. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15. quiz 16–18. - PubMed